Latest & greatest articles for cardiovascular disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cardiovascular disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cardiovascular disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cardiovascular disease

1. Outcome and Cost of Optimal Control of Dyslipidemia in Adults with High Risk for Cardiovascular Disease

. Med. 2017; 167 : Itc81-itc96 World Health Organization. The World Health Report 2002: Quantifying Selected Major Risks to Health2002:49-97. Halcox J.P. Banegas J.R. Roy C. et al. Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study. BMC Cardiovasc. Disord. 2017; 17 : 160 Zwald ML, Akinbami LJ, Fakhouri TH, Fryar CD. Prevalence of Low High-density Lipoprotein Cholesterol Among Adults (...) of statins: rationale and design of the ODYSSEY COMBO I and II trials. BMC Cardiovasc. Disord. 2014; 14 : 121 Sabatine M.S. Giugliano R.P. Keech A.C. et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N. Engl. J. Med. 2017; 376 : 1713-1722 Article Info Publication History Accepted: March 17, 2020 Received in revised form: February 28, 2020 Received: November 4, 2019 Publication stage In Press Journal Pre-Proof Identification DOI: Copyright © 2020 Published by Elsevier Inc

2020 Institute of Health Economics

2. Position Statement on Optimising Secondary Prevention and Cardiac Rehabilitation for Atherosclerotic Cardiovascular Disease During the COVID-19 Pandemic

Position Statement on Optimising Secondary Prevention and Cardiac Rehabilitation for Atherosclerotic Cardiovascular Disease During the COVID-19 Pandemic 1 Optimising Secondary Prevention and Cardiac Rehabilitation for Atherosclerotic Cardiovascular Disease During the COVID-19 Pandemic: A Position Statement by the Cardiac Society of Australia and New Zealand Stephen J Nicholls 1 , Mark Nelson 2 , Carolyn Astley 3 , Tom Briffa 4 , Alex Brown 5 , Robyn Clark 3 , David Colquhoun 6 , Robyn Gallagher (...) care across the world. In addition to the described cardiovascular disease (CVD) complications of COVID-19, including myocarditis, myocardial injury, arrhythmia and thromboembolism, the pandemic has additional implications for the management of the patient with established atherosclerotic CVD. In particular, it provides challenges for the use and introduction of secondary prevention measures. This position statement provides recommendations for effective delivery of secondary prevention strategies

2020 Cardiac Society of Australia and New Zealand

3. Cardiovascular disease and COVID-19: Australian/New Zealand consensus statement

Abstract Introduction: The Coronavirus-19 disease (COVID-19) pandemic is caused by acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Pre-existing cardiovascular disease (CVD) increases the morbidity and mortality of COVID-19, and COVID-19 itself causes serious cardiac sequelae. Strategies to minimise the risk of viral transmission to healthcare workers and uninfected cardiac patients while prioritising high quality cardiac care are urgently needed. We conducted a rapid literature appraisal (...) 2 MI (28). Myocardial injury in COVID-19 patients can manifest with ST-elevation in the absence of obstructive coronary artery disease (CAD). Whether this is due to microvascular injury or myocarditis is unclear. To avoid unnecessary coronary angiography during the acute illness, haemodynamically stable patients with COVID-19 and possible MI may be best managed conservatively, with invasive procedures deferred until after COVID-19 recovery. Cardiovascular implications of novel therapies Numerous

2020 Cardiac Society of Australia and New Zealand

4. Strategies For Risk Reduction and Management of Older Adults With Cardiovascular Disease During the COVID-19 Pandemic

Strategies For Risk Reduction and Management of Older Adults With Cardiovascular Disease During the COVID-19 Pandemic Strategies For Risk Reduction and Management of Older Adults With Cardiovascular Disease During the COVID-19 Pandemic - American College of Cardiology ') Search All Types Search or Menu . This article was authored by Nicole M. Orr, MD, FACC , and the Geriatric Cardiology Council. Share via: Clinical Topics: Keywords: Aged, SARS Virus, Angiotensin Receptor Antagonists (...) , Hydroxychloroquine, Mineralocorticoid Receptor Antagonists, Caregivers, Angiotensin-Converting Enzyme Inhibitors, COVID-19, Coronavirus, Coronavirus Infections, Neprilysin, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Neprilysin, Chloroquine, Subacute Care, Social Isolation, Skilled Nursing Facilities, Cardiovascular Diseases > > Strategies For Risk Reduction and Management of Older Adults With Cardiovascular Disease During the COVID-19 Pandemic Heart House 2400 N Street NW Washington, DC 20037 Phone: , ext

2020 American College of Cardiology

5. Key Questions on COVID-19 and Cardiovascular Disease

SQC Approval Date: April 24, 2020 Patients with cardiovascular conditions, especially poorly controlled disease, are at higher risk for COVID-19 complications. As such, they should be counseled to avoid situations that would put them at risk for SARS CoV2 exposure. They, along with their physician, should evaluate their workplace and determine if undue risk exists. If so, mitigation strategies should be considered. These include minimizing face-to-face contact between employees, assigning work (...) Syndrome X, Angina, Stable, Heart Defects, Congenital, Dyslipidemias, Geriatrics, Heart Failure, Angiography, Diagnostic Imaging, Pericarditis, Secondary Prevention, Hypertension, Pulmonary, Sleep Apnea Syndromes, Sports, Angina, Stable, Exercise Test, Heart Valve Diseases, Aneurysm, COVID-19, Coronavirus, Coronavirus Infections, Cardiology Magazine, ACC Publications > > Feature | Key Questions on COVID-19 and Cardiovascular Disease Heart House 2400 N Street NW Washington, DC 20037 Phone: , ext. 5603

2020 American College of Cardiology

6. Comparing Major Bleeding Risk in Outpatients With Atrial Fibrillation or Flutter by Oral Anticoagulant Type (from the National Cardiovascular Disease Registry`s Practice Innovation and Clinical Excellence Registry)

Comparing Major Bleeding Risk in Outpatients With Atrial Fibrillation or Flutter by Oral Anticoagulant Type (from the National Cardiovascular Disease Registry`s Practice Innovation and Clinical Excellence Registry) Comparing Major Bleeding Risk in Outpatients With Atrial Fibrillation or Flutter by Oral Anticoagulant Type (From the National Cardiovascular Disease Registry's Practice Innovation and Clinical Excellence Registry) - PubMed This site needs JavaScript to work properly. Please enable (...) when there aren't any new results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Actions Cite Share Permalink Copy Page navigation Am J Cardiol Actions . 2020 May 15;125(10):1500-1507. doi: 10.1016/j.amjcard.2020.02.028. Epub 2020 Mar 5. Comparing Major Bleeding Risk in Outpatients With Atrial Fibrillation or Flutter by Oral Anticoagulant Type (From the National Cardiovascular Disease Registry's Practice Innovation and Clinical

2020 EvidenceUpdates

7. Palliative Care Considerations For Patients With Cardiovascular Disease Under COVID-19

Palliative Care Considerations For Patients With Cardiovascular Disease Under COVID-19 Palliative Care Considerations For Patients With Cardiovascular Disease Under COVID-19 - American College of Cardiology ') Search All Types Search or Menu CBT=cognitive behavioral therapy; IV=intravenous; po=by mouth; SL=sublingually + People with Parkinsonism, Lewy body disease or pre-existing cogwheel rigidity, for whom haloperidol is contraindicated, quetiapine 12.5-25 mg orally up to 4 times daily can (...) to the surge in deaths in most communities. Bereavement support and acknowledgement of both our loss as clinicians, and the family's loss should be routine after a death. Provider Resiliency The cardiovascular care team is immersed on the front lines preparing for the surge of COVID-19 patients or already deeply engaged depending on location. Usual stress and long hours have been superseded by novel adversaries. Clinicians work lacking PPE in a new environment, with risks of COVID-19 illness and mortality

2020 American College of Cardiology

8. Canadian Cardiovascular Society Position Statement on Postural Orthostatic Tachycardia Syndrome (POTS) and Related Disorders of Chronic Orthostatic Intolerance Full Text available with Trip Pro

problem of nomenclature that inhibited effective communication became apparent, and this contributed to mistaken diagnoses of POTS. One issue was that even within the expert panel, there was disagreement about whether POTS was a purely cardiovascular and hemodynamic disorder, or one that could be associated with other disorders with systemic (and nonhemodynamic) presentations. Some believed that if a patient had another condition (eg, Ehlers-Danlos syndrome) that they should not be diagnosed with POTS (...) Canadian Cardiovascular Society Position Statement on Postural Orthostatic Tachycardia Syndrome (POTS) and Related Disorders of Chronic Orthostatic Intolerance Canadian Cardiovascular Society Position Statement on Postural Orthostatic Tachycardia Syndrome (POTS) and Related Disorders of Chronic Orthostatic Intolerance - Canadian Journal of Cardiology Go search , P357-372, March 01, 2020 Powered By Mendeley Share on Canadian Cardiovascular Society Position Statement on Postural Orthostatic

2020 Canadian Cardiovascular Society

9. The use of statins in the primary prevention of cardiovascular disease: an online tool for shared-decision making

The use of statins in the primary prevention of cardiovascular disease: an online tool for shared-decision making 2019 www.kce.fgov.be KCE REPORT 324 THE USE OF STATINS IN THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE: AN ONLINE TOOL FOR SHARED- DECISION MAKING 2019 www.kce.fgov.be KCE REPORT 324 HEALTH TECHNOLOGY ASSESSMENT THE USE OF STATINS IN THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE: AN ONLINE TOOL FOR SHARED-DECISION MAKING CHRISTOPHE DE MEESTER (KCE), KARIN RONDIA (KCE), THOMAS (...) GOORDEN (LEF), SABINE JANSSENS (BSM), PIETER STEYAERT (TEMPERA), CHRIS DE LAET (KCE), MICHEL ALBERTIJN (TEMPERA), LAURENCE KOHN (KCE) COLOPHON Title: The use of statins in the primary prevention of cardiovascular disease: an online tool for shared-decision making Authors: Christophe De Meester (KCE), Karin Rondia (KCE), Thomas Goorden (LEF), Sabine Janssens (BSM), Pieter Steyaert (Tempera), Chris De Laet (KCE), Michel Albertijn (Tempera), Laurence Kohn (KCE) Information specialist: Nicolas Fairon (KCE

2020 Belgian Health Care Knowledge Centre

10. Cardiovascular Disease: Tailored Pharmacy-based Interventions to Improve Medication Adherence

disease prevention medications at least 80% of the time. The proportion of patients considered adherent increased by a median of 6.9 percentage points (an increase of ≈ 9.9%) The remaining 21 studies used various tools to measure adherence (e.g., objective provider counts or records, self-report) and reported generally favorable results. Cardiovascular Disease Risk Conditions A subset of 17 studies evaluated intervention effects on blood pressure control and lipid control. There was a median increase (...) " or "cardiovascular diseases").mp. 33. ("cerebrovascular disease" or "cerebrovascular diseases" or "cerebrovascular event" or "cerebrovascular events" or "angina" or "coronary disease" or "coronary artery disease" or "ischemia" or "myocardial ischemic preconditioning").mp. 34. ("transient ischemic attack" or "brain hypoxia ischemia" or "myocardial ischemia" or "heart diseases" or "myocardial infarction" or "stroke" or "cerebrovascular disorders" or "basal ganglia cerebrovascular disease").mp. 35. (angina pectoris

2020 Community Preventive Services Task Force

11. Cardiovascular disease prevention: applying All Our Health

Cardiovascular disease prevention: applying All Our Health Cardiovascular disease prevention: applying All Our Health - GOV.UK Tell us whether you accept cookies We use about how you use GOV.UK. We use this information to make the website work as well as possible and improve government services. Accept all cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance Cardiovascular disease prevention: applying All Our Health Evidence and guidance to help healthcare (...) professionals to prevent heart attacks, strokes and dementia and to improve cardiovascular health. Published 9 January 2019 Last updated 16 December 2019 — From: Documents HTML Details This resource helps: front-line health professionals team leaders or managers senior or strategic leaders to prevent ill health and promote wellbeing as part of their everyday practice. We also recommend important actions that managers and staff holding strategic roles can take. View the full range of topics. Published 9

2020 Public Health England

12. Development and validation of a cardiovascular risk score for patients in the community after acute coronary syndrome

Development and validation of a cardiovascular risk score for patients in the community after acute coronary syndrome Development and Validation of a Cardiovascular Risk Score for Patients in the Community After Acute Coronary Syndrome - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several other advanced features are temporarily (...) : Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Heart Actions 2019 Dec 10 [Online ahead of print] Development and Validation of a Cardiovascular Risk Score for Patients in the Community After Acute Coronary Syndrome , , , , , , , , Affiliations Expand Affiliations 1 Epidemiology & Biostatistics, University of Auckland, Auckland, New Zealand

2020 EvidenceUpdates

13. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China Full Text available with Trip Pro

. The incidence of acute cardiac injury was about 13 folds higher in ICU/severe patients compared with the non-ICU/severe patients. Conclusion Patients with previous cardiovascular metabolic diseases may face a greater risk of developing into the severe condition and the comorbidities can also greatly affect the prognosis of the COVID-19. On the other hand, COVID-19 can, in turn, aggravate the damage to the heart. Introduction During the past two decades, the outbreak and prevalence of severe acute (...) of coronaviruses. Trends Microbiol 24:490–502 19. Cui J, Li F, Shi ZL (2019) Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol 17:181–192 20. Chan JW, Ng CK, Chan YH, Mok TY, Lee S, Chu SY, Law WL, Lee MP, Li PC (2003) Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS). Thorax 58:686–689 21. Hu S, Gao R, Liu L, Zhu M, Wang W, Wang Y, Wu Z, Li H, Gu D, Yang Y (2019) Summary of the 2018 report on cardiovascular diseases

2020 Covid-19 Ad hoc papers

14. Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the Coronavirus Disease 2019 (COVID-19) Pandemic Full Text available with Trip Pro

Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the Coronavirus Disease 2019 (COVID-19) Pandemic Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the Coronavirus Disease 2019 (COVID-19) Pandemic | JACC: Journal of the American College of Cardiology Advertisement User menu Source Search for this keyword Search Source Search for this keyword Search Journal of the American College of Cardiology DOI: 10.1016/j.jacc (...) .2020.03.031 JACC State-of-the-Art Review Just Accepted Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the Coronavirus Disease 2019 (COVID-19) Pandemic Elissa Driggin , Mahesh V. Madhavan , Behnood Bikdeli , Taylor Chuich , Justin Laracy , Giuseppe Bondi-Zoccai , Tyler S. Brown , Caroline Der Nigoghossian , David A. Zidar , Jennifer Haythe , Daniel Brodie , Joshua A. Beckman , Ajay J. Kirtane , Gregg W. Stone , Harlan M. Krumholz and Sahil A. Parikh Author

2020 American College of Cardiology

15. CSC Expert Consensus on Principles of Clinical Management of Patients with Severe Emergent Cardiovascular Diseases during the COVID-19 Epidemic

, and strict measures to limit infection spread within the hospital and to healthcare workers. 1. Risk assessment Downloaded from http://ahajournals.org by on April 10, 202010.1161/CIRCULATIONAHA.120.047011 7 The purpose of risk assessment is to carefully weigh the relative advantages and disadvantages of treating cardiovascular disease all while preventing the risk of SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) transmission. During the period of epidemic, under the premise of minimizing (...) CSC Expert Consensus on Principles of Clinical Management of Patients with Severe Emergent Cardiovascular Diseases during the COVID-19 Epidemic 10.1161/CIRCULATIONAHA.120.047011 1 CSC Expert Consensus on Principles of Clinical Management of Patients with Severe Emergent Cardiovascular Diseases during the COVID-19 Epidemic Running Title: Han et al.; Consensus on Managing CVD during COVID-19 Epidemic Yaling Han, MD, FACC, FAHA, Chair 1 ; Hesong Zeng, MD, co-chair 2 ; Hong Jiang, MD, FACC, co

2020 Covid-19 Ad hoc guidelines

16. COVID-19 and Cardiovascular Disease Patients

disease Reference - Cardiovascular presentations acute cardiovascular presentations associated with COVID-19 may include acute myocardial injury without obstructive coronary artery disease which may present with elevated troponin with or without additional symptoms arrhythmias such as atrial arrhythmias ventricular tachycardia ventricular fibrillation acute coronary syndrome (ST-segment elevation myocardial infraction [STEMI] or non-ST segment elevation myocardial infarction [NSTEMI]) with obstructive (...) ischemia and nonischemic myocardial processes may occur in patients with severe respiratory infection and hypoxia, especially if acute respiratory distress syndrome (ARDS) elevated troponin levels can be present in patients with renal insufficiency due to delayed excretion, especially if advanced disease Reference - cardiovascular complications may occur due to various mechanisms including direct myocardial injury resulting from binding of SARS-CoV-2 virus to angiotensin-converting enzyme 2 (ACE2

2020 DynaMed Plus

17. Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis Full Text available with Trip Pro

Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis Lowering low-density lipoprotein cholesterol (LDL-C) reduces cardiovascular risk irrespective of age, but the evidence is less strong for older patients.This prespecified analysis from ODYSSEY OUTCOMES compared the effect of alirocumab vs. placebo in 18 924 patients with recent acute coronary syndrome (ACS) according to age. We examined the effect of assigned (...) treatment on occurrence of the primary study outcome, a composite of coronary heart disease death, myocardial infarction, ischaemic stroke, or unstable angina requiring hospitalization [major adverse cardiovascular event (MACE)] and all-cause death. Relative risk reductions were consistent for patients ≥65 vs. <65 years for MACE [hazard ratio (HR) 0.78, 95% confidence interval (CI) 0.68-0.91 vs. 0.89, 0.80-1.00; Pinteraction = 0.19] and all-cause death [HR 0.77, 0.62-0.95 vs. 0.94, 0.77-1.15

2019 EvidenceUpdates

18. Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV: A Scientific Statement From the American Heart Association

Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV: A Scientific Statement From the American Heart Association Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV: A Scientific Statement From the American Heart Association | Circulation Search Hello Guest! Login to your account Email Password Keep me logged in Search December 2019 November 2019 October 2019 September 2019 August 2019 July 2019 June 2019 May (...) 2019 April 2019 March 2019 February 2019 January 2019 This site uses cookies. By continuing to browse this site you are agreeing to our use of cookies. Free Access article Share on Jump to Free Access article Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV: A Scientific Statement From the American Heart Association , MD, MSc, FAHA, Chair , MD, Vice Chair , PhD , MD, MPH, FAHA , MD , MD, MSc , MD , MS , MD, FAHA , MD, MS Matthew J. Feinstein

2019 American Heart Association

19. Cardiovascular disease data and analysis: guide for health professionals

with cardiovascular disease ( for further information on cardiovascular disease conditions. can help healthcare professionals make decisions about how to improve local primary care. There is a pack with local , looking at coronary heart disease, diabetes, kidney disease and stroke. The profiles compare the subject that include information on the inpatient care of people with diabetes who are admitted to hospital for a range of footcare conditions. The profiles compare data from the subject Spending on care (...) Cardiovascular disease data and analysis: guide for health professionals Cardiovascular disease data and analysis: guide for health professionals - GOV.UK GOV.UK uses cookies which are essential for the site to work. We also use non-essential cookies to help us improve government digital services. Any data collected is anonymised. By continuing to use this site, you agree to our use of cookies. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Register by 26 November

2019 Public Health England

20. Comparison of Frequency of Atherosclerotic Cardiovascular Disease Events Among Primary and Secondary Prevention Subgroups of the Systolic Blood Pressure Intervention Trial (Abstract)

Comparison of Frequency of Atherosclerotic Cardiovascular Disease Events Among Primary and Secondary Prevention Subgroups of the Systolic Blood Pressure Intervention Trial The Pooled Cohort Equation (PCE) predicts 10-year risk of first-time atherosclerotic cardiovascular disease (ASCVD) events and was incorporated in analyses of a primary and secondary prevention population in the Systolic Blood Pressure Intervention Trial (SPRINT). Whether PCE enhances risk prediction among secondary

2019 EvidenceUpdates